Lancet Oncol
May 2017
Background: Maintenance therapy improves outcomes in various tumour types, but cumulative toxic effects limit the choice of drugs. We investigated whether maintenance therapy with vinflunine would delay disease progression in patients with advanced urothelial carcinoma who had achieved disease control with first-line chemotherapy.
Methods: We did a randomised, controlled, open-label, phase 2 trial in 21 Spanish hospitals.